recommended reading

Is the CDC Wrong to Endorse Tamiflu?

Charlie Neibergall/AP

Flu season is still here, and Hoffman-LaRoche, the manufacturer of the anti-viral drug Tamiflu (oseltamivir) are still running an ad intended to market directly to patients. "Sometimes what we suffer from is bigger than we think. The flu is a big deal, so don't treat it like a little cold. Treat it with Tamiflu." 

If you didn't get the message from these ads, the U.S. Centers for Disease Control and Prevention has also issued public service announcements urging people to get Tamiflu at the first sign of a sniffle or sneeze. 

Between the two, the government recommendations and pharmaceutical ads appear to be having the desired effect, because Americans have been flooding their local emergency rooms and doctor's offices asking for their prescription of Tamiflu.

Emergency physicians tell us their beds and hallways are jammed with people complaining of flu-like symptoms. And for those doctors who might be tempted to tell their patients to go home, take two aspirin, and get back into bed, Roche has been targeting the doctors with another set of marketing messages. In its ads to physicians, the company claimed that Tamiflu cuts hospital admissions by 61 percent and reduces complications such as bronchitis, pneumonia, and sinusitis by 67 percent. In at least one press release, the company even claimed that the drug reduces flu deaths.

The drug does none of the above. An FDA committee declined to approve Tamiflu in 1999 after finding that Tamiflu had not been shown to reduce pneumonia or mortality. But FDA administrators overruled the expert advisors and approved the drug.

Read more at The Atlantic

Threatwatch Alert

Stolen laptop

Wireless Heart Monitor Maker to Pay $2.5M Settlement to HHS After Laptop Stolen

See threatwatch report

JOIN THE DISCUSSION

Close [ x ] More from Nextgov
 
 

Thank you for subscribing to newsletters from Nextgov.com.
We think these reports might interest you:

  • Modernizing IT for Mission Success

    Surveying Federal and Defense Leaders on Priorities and Challenges at the Tactical Edge

    Download
  • Communicating Innovation in Federal Government

    Federal Government spending on ‘obsolete technology’ continues to increase. Supporting the twin pillars of improved digital service delivery for citizens on the one hand, and the increasingly optimized and flexible working practices for federal employees on the other, are neither easy nor inexpensive tasks. This whitepaper explores how federal agencies can leverage the value of existing agency technology assets while offering IT leaders the ability to implement the kind of employee productivity, citizen service improvements and security demanded by federal oversight.

    Download
  • Effective Ransomware Response

    This whitepaper provides an overview and understanding of ransomware and how to successfully combat it.

    Download
  • Forecasting Cloud's Future

    Conversations with Federal, State, and Local Technology Leaders on Cloud-Driven Digital Transformation

    Download
  • IT Transformation Trends: Flash Storage as a Strategic IT Asset

    MIT Technology Review: Flash Storage As a Strategic IT Asset For the first time in decades, IT leaders now consider all-flash storage as a strategic IT asset. IT has become a new operating model that enables self-service with high performance, density and resiliency. It also offers the self-service agility of the public cloud combined with the security, performance, and cost-effectiveness of a private cloud. Download this MIT Technology Review paper to learn more about how all-flash storage is transforming the data center.

    Download

When you download a report, your information may be shared with the underwriters of that document.